ASML's Buyback, a Downgrade and a Patent Trail: Three Signals, Three Different Questions
Published on 10/24/2026 at 17:02 | Editorial boerse-global.de
ASML finds itself on the receiving end of a mixed bag of news this week, and the temptation to read it as a single verdict on the stock is one investors would do well to resist. A broker downgrade, a fresh patent trail and a share buyback all landed within days of each other â yet each speaks to a separate part of the story.
JLPascual cut ASML to "Sell" on 17 October, according to media reports, attaching a price target of $749. The skeptical call sits alongside something rather more speculative: research suggesting the Dutch equipment maker may be quietly developing a new product line.
That speculation traces back to SemiAnalysis, which examined 27 patent filings and concluded that ASML could be working on systems for hybrid bonding. Reuters reported on the analysis on 16 October. ASML has not confirmed any such product.
The distinction matters. Patent applications point to possible development work; they prove neither an imminent launch nor future revenue from such tools. No confirmed additional revenue driver can be extracted from the technical breadcrumb trail just yet.
Should investors sell immediately? Or is it worth buying ASML Holding?
Two Answers to Two Different Questions
The downgrade and the patent report should not be blended into one statement about the business outlook. The sell rating concerns how the equity is valued. The patent analysis describes a possible direction for the technology. The potential product development, in particular, is no confirmed rebuttal to the skeptical call.
Far firmer ground comes from what ASML has actually said about its existing business. Reuters reported on 15 October that the company is weighing roughly a dozen additional EUV machines per year beyond the capacity previously planned for 2028, driven by expectations that demand will outstrip planned supply.
That is a considered expansion, not a decided or completed one â a distinction that separates the prospect of extra capacity from the volume ASML can actually deliver.
The Supply Gap Is the Hard Fact
In its quarterly results published about two weeks ago, ASML said planned supply would not fully meet customer demand in either 2027 or 2028. At the same time, it lifted its full-year 2026 revenue forecast to between EUR 44 billion and EUR 45 billion.
Those confirmed statements currently carry more weight for investment decisions than the possible new product category. The demand overhang supports the business outlook, while delivery capacity limits how much of it can be converted. The patent trail opens an additional angle but remains unconfirmed; the sell rating strikes a skeptical counterpoint without refuting the operating demand picture.
Capital returns add another layer. On Monday, ASML disclosed the repurchase of 233,867 shares for a total of EUR 352,032,719. The purchases were made under the ongoing buyback program between 12 and 16 October, with no repurchases reported for 14 October.
The disclosure documents executed purchases rather than an intention to buy, and it concerns how the company uses its capital â a separate matter from how quickly it can ship additional equipment to customers.
Terafab: One Project, Not the Whole Order Book
That shipping question sits behind the latest news on the joint SpaceX-Tesla venture. Reuters reported on Tuesday that Elon Musk said ASML and other suppliers had accelerated equipment deliveries for Terafab, a project targeting high-volume chip production in the third quarter of 2028.
ASML Holding at a turning point? This analysis reveals what investors need to know now.
The statement covers deliveries for that specific project. It is not a commitment by ASML to serve all expected demand, and the start of production remains a target rather than a reached milestone.
Read together, the accelerated deliveries and the capacity warning are consistent: individual shipments can move faster while overall planned supply stays behind customer needs. Management is therefore examining extra capacity for the later of the two years.
What the Numbers Say
ASML posted net sales of EUR 11.662 billion and net profit of EUR 4.960 billion in the third quarter of 2026. For the fourth quarter, it forecasts net sales of EUR 14.2 billion to EUR 15.2 billion.
The raised revenue guidance provides the financial backdrop to this week's headlines, though the various statements operate on different planes. The quarterly figures describe business already booked; the buyback disclosure evidences capital returned to shareholders. The delivery and capacity comments, by contrast, concern how future demand will be served. Near term, hitting that fourth-quarter range is the operative yardstick; over the longer haul, what counts is how far the capacity build-out can narrow the expected supply gap.
Ad
ASML Holding Stock: New Analysis - 24 October
Fresh ASML Holding information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
